PARP Inhibitors for the Treatment of BRCA1/ 2-Mutated Metastatic Breast Cancer: A Systematic Review and Meta-analysis
Background: The PARP inhibitors (PARPis) olaparib and talazoparib are currently approved for the treatment of deleterious germline BRCA1/2-mutated (gBRCA+) metastatic breast cancer (MBC). These approvals were based on improvements in progression-free survival (PFS) observed in two randomized control...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Wolters Kluwer Medknow Publications
2023-07-01
|
| Colección: | Hematology/Oncology and Stem Cell Therapy |
| Materias: | |
| Acceso en línea: | https://journals.lww.com/10.56875/2589-0646.1033 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|